These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 33976166)
1. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Huda A; Castaño A; Niyogi A; Schumacher J; Stewart M; Bruno M; Hu M; Ahmad FS; Deo RC; Shah SJ Nat Commun; 2021 May; 12(1):2725. PubMed ID: 33976166 [TBL] [Abstract][Full Text] [Related]
2. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy. Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306 [TBL] [Abstract][Full Text] [Related]
3. Machine Learning Identifies Plasma Metabolites Associated With Heart Failure in Underrepresented Populations With the Park JK; Petrazzini BO; Saha A; Vaid A; Vy HMT; Márquez-Luna C; Chan L; Nadkarni GN; Do R J Am Heart Assoc; 2023 Apr; 12(8):e027736. PubMed ID: 37042260 [No Abstract] [Full Text] [Related]
4. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis. Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374 [No Abstract] [Full Text] [Related]
6. Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk. Willis C; Watanabe AH; Hughes J; Nolen K; O'Meara J; Schepart A; Bruno M; Biskupiak J; Kawamoto K; Shara N; Kannampallil T Future Cardiol; 2022 May; 18(5):367-376. PubMed ID: 35098741 [No Abstract] [Full Text] [Related]
7. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C; J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769 [TBL] [Abstract][Full Text] [Related]
8. Transthyretin Cardiac Amyloidosis Due to Homozygous Val122Ile Mutation in a Caucasian Man. Marrero Negrín N; Medina Gil JM; García Cruz ML; Jiménez Cabrera F Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1086-1088. PubMed ID: 31561982 [No Abstract] [Full Text] [Related]
9. Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy. Muller SA; Oerlemans MIFJ Eur J Heart Fail; 2023 Jun; 25(6):854-856. PubMed ID: 37191114 [No Abstract] [Full Text] [Related]
10. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy. Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637 [No Abstract] [Full Text] [Related]
11. Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model. Bruno M; Sheer R; Reed C; Schepart A; Nair R; Simmons JD J Manag Care Spec Pharm; 2023 May; 29(5):530-540. PubMed ID: 37121249 [No Abstract] [Full Text] [Related]